Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-M23 in relapsed and refractory epithelial ovarian cancer
NCT04562298Phase 1Terminated
- Sponsor
- Shanghai East Hospital
- Start
- Oct 2020
- Primary completion
- Jun 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MSLN CAR-T TGFβRIIDN in epithelial ovarian cancer (EOC), sponsored by Shanghai East Hospital. Primary endpoints: Dose-limiting toxicity at 90 days, Treatment-emergent adverse events at 90 days and 2 more. Started Oct 2020; status: terminated.
02
Drugs
MSLN CAR-T TGFβRIIDN
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT04562298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562298.